Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Upadacitinib, a Janus kinase 1 inhibitor, demonstrated comparable safety and effectiveness over 2 years in patients with moderate to severe atopic dermatitis (AD), regardless of smoking status.

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Atopic dermatitis is the most common form of eczema ... inhibitors including Cibinqo (abrocitinib) and Rinvoq (upadacitinib) are other treatment options. Applying a cool compress to the affected ...

Upadacitinib sustains its efficacy in non-radiographic axial spondyloarthritis through 2 years without presenting any new ...

The drug is also being studied in other immune-mediated diseases – phase 3 trials of upadacitinib in atopic dermatitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis are ongoing ...

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which ... Sciences’ filgotinib and AbbVie’s upadacitinib. These are being developed ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...